Evidence map›Paper›PMID 26102296›Full record

ArticleNature communications2015

Ganoderma lucidum reduces obesity in mice by modulating the composition of the gut microbiota.

Chih-Jung Chang, Chuan-Sheng Lin, Chia-Chen Lu, Jan Martel, Yun-Fei Ko, David M Ojcius, Shun-Fu Tseng, Tsung-Ru Wu, Yi-Yuan Margaret Chen, John D Young and 1 more

Erratum issued Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Nature communications, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT04821258 (Double-blind Randomized Clinical Trial to Evaluate the Effect of the Nutraceutical "MICODIGEST 2.0" on the Complications After Surgery With Curative Intent for Colorectal Cancer), which is not on this map. Cited by 467 papers.

0numbers the graph read from it
0cells of the map it votes in
467citing papers in PubMed
28.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04821258 naunknown statusnot on this mapstarted 2021, after this paper: background citation

Double-blind Randomized Clinical Trial to Evaluate the Effect of the Nutraceutical "MICODIGEST 2.0" on the Complications After Surgery With Curative Intent for Colorectal Cancer

TypeinterventionalSponsorFundacin Biomedica Galicia SurRan2021 to 2022Enrolled144ConditionsColorectal Cancer, Surgery--ComplicationsArmsMICODIGEST 2.0 supplement, Placebo supplement
3 · Its place in the literature

Who cites it

467 citing papers in PubMed, 1,244 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. DietaryCurrent issues in molecular biology · 2026
    Article
  8. Article
  9. Review
  10. International journal of molecular medicine · 2026
    Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. [Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026
    Article
  19. Review
  20. Article

407 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Chih-Jung Chang1] Center for Molecular and Clinical Immunology, Chang Gung University, Gueishan, Taoyuan 33302, Taiwan, ROC [2] Department of Medical Biotechnology and Laboratory Science, College of Medicine, Chang Gung University, Gueishan, Taoyuan 33302, Taiwan, ROC [3] Department of Laboratory Medicine, Chang Gung Memorial Hospital, Linkou, Gueishan, Taoyuan 33305, Taiwan, ROC [4] Department of Microbiology and Immunology, Chang Gung University, Gueishan, Taoyuan 33302, Taiwan, ROC [5] Research Center of Bacterial Pathogenesis, Chang Gung University, Gueishan, Taoyuan 33302, Taiwan, ROC.
Chuan-Sheng Lin1] Center for Molecular and Clinical Immunology, Chang Gung University, Gueishan, Taoyuan 33302, Taiwan, ROC [2] Department of Medical Biotechnology and Laboratory Science, College of Medicine, Chang Gung University, Gueishan, Taoyuan 33302, Taiwan, ROC [3] Department of Laboratory Medicine, Chang Gung Memorial Hospital, Linkou, Gueishan, Taoyuan 33305, Taiwan, ROC [4] Research Center of Bacterial Pathogenesis, Chang Gung University, Gueishan, Taoyuan 33302, Taiwan, ROC.
Chia-Chen LuDepartment of Respiratory Therapy, Fu Jen Catholic University, Xinzhuang, New Taipei City 24205, Taiwan, ROC.
Jan MartelCenter for Molecular and Clinical Immunology, Chang Gung University, Gueishan, Taoyuan 33302, Taiwan, ROC.
Yun-Fei Ko1] Chang Gung Biotechnology Corporation, Taipei 10508, Taiwan, ROC [2] Biochemical Engineering Research Center, Ming Chi University of Technology, Taishan, New Taipei City 24301, Taiwan, ROC.
David M Ojcius1] Center for Molecular and Clinical Immunology, Chang Gung University, Gueishan, Taoyuan 33302, Taiwan, ROC [2] Department of Biomedical Sciences, University of the Pacific, Arthur Dugoni School of Dentistry, San Francisco, California 94103, USA.
Shun-Fu TsengResearch Center of Bacterial Pathogenesis, Chang Gung University, Gueishan, Taoyuan 33302, Taiwan, ROC.
Tsung-Ru Wu1] Department of Medical Biotechnology and Laboratory Science, College of Medicine, Chang Gung University, Gueishan, Taoyuan 33302, Taiwan, ROC [2] Department of Laboratory Medicine, Chang Gung Memorial Hospital, Linkou, Gueishan, Taoyuan 33305, Taiwan, ROC.
Yi-Yuan Margaret ChenDepartment of Microbiology and Immunology, Chang Gung University, Gueishan, Taoyuan 33302, Taiwan, ROC.
John D Young1] Center for Molecular and Clinical Immunology, Chang Gung University, Gueishan, Taoyuan 33302, Taiwan, ROC [2] Chang Gung Biotechnology Corporation, Taipei 10508, Taiwan, ROC [3] Biochemical Engineering Research Center, Ming Chi University of Technology, Taishan, New Taipei City 24301, Taiwan, ROC [4] Laboratory of Cellular Physiology and Immunology, Rockefeller University, New York, New York 10021, USA.
Hsin-Chih Lai1] Center for Molecular and Clinical Immunology, Chang Gung University, Gueishan, Taoyuan 33302, Taiwan, ROC [2] Department of Medical Biotechnology and Laboratory Science, College of Medicine, Chang Gung University, Gueishan, Taoyuan 33302, Taiwan, ROC [3] Department of Laboratory Medicine, Chang Gung Memorial Hospital, Linkou, Gueishan, Taoyuan 33305, Taiwan, ROC [4] Research Center of Bacterial Pathogenesis, Chang Gung University, Gueishan, Taoyuan 33302, Taiwan, ROC.
Chang Gung University · TWChang Gung Memorial Hospital · TWFu Jen Catholic University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Obesity is associated with low-grade chronic inflammation and intestinal dysbiosis. Ganoderma lucidum is a medicinal mushroom used in traditional Chinese medicine with putative anti-diabetic effects. Here, we show that a water extract of Ganoderma lucidum mycelium (WEGL) reduces body weight, inflammation and insulin resistance in mice fed a high-fat diet (HFD). Our data indicate that WEGL not only reverses HFD-induced gut dysbiosis-as indicated by the decreased Firmicutes-to-Bacteroidetes ratios and endotoxin-bearing Proteobacteria levels-but also maintains intestinal barrier integrity and reduces metabolic endotoxemia. The anti-obesity and microbiota-modulating effects are transmissible via horizontal faeces transfer from WEGL-treated mice to HFD-fed mice. We further show that high molecular weight polysaccharides (>300 kDa) isolated from the WEGL extract produce similar anti-obesity and microbiota-modulating effects. Our results indicate that G. lucidum and its high molecular weight polysaccharides may be used as prebiotic agents to prevent gut dysbiosis and obesity-related metabolic disorders in obese individuals.

Indexed as

Insulin ResistanceReishiAnimalsBacillotaBacteroidesBody WeightDiet, High-FatDrugs, Chinese HerbalDysbiosisEndotoxemiaFecal Microbiota TransplantationFungal PolysaccharidesGastrointestinal MicrobiomeInflammationIntestinal MucosaIntestinesDrugs, Chinese HerbalFungal PolysaccharidesPlant Extracts

Identifiers

PMID26102296
PMCPMC4557287
OpenAlexW1919048856

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.